• Target CEO: We are taking 'enormous' market share in cosmetics
    Yahoo Finance

    Target CEO: We are taking 'enormous' market share in cosmetics

    Target CEO Brian Cornell talks with Yahoo Finance about the company's success down the cosmetics aisle.

  • Hedge Funds Are Dumping Nordson Corporation (NDSN)
    Insider Monkey

    Hedge Funds Are Dumping Nordson Corporation (NDSN)

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • Is Weibo Corporation (WB) A Good Stock To Buy?
    Insider Monkey

    Is Weibo Corporation (WB) A Good Stock To Buy?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]

  • There’s more upside for biotech even after 24% gains in two months
    MarketWatch

    There’s more upside for biotech even after 24% gains in two months

    Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund (XBI) is up 24%, and the iShares Nasdaq Biotechnology Index (IBB)  has advanced 20%, compared with 5.2% for the S&P 500 (SPX) The seven stocks I singled out in that column have done well. “Washington is very focused on impeachment and trade talks,” says Jefferies biotech analyst Michael Yee.

  • 5 Stocks to Sell or Avoid in 2020
    Kiplinger

    5 Stocks to Sell or Avoid in 2020

    Sometimes, it pays to fold 'em.While many investors gear up for the new year by scouting out lists of the best stocks to buy, there's virtue in pruning, too. Even though it seems counterintuitive to sell into a rip-snorting bull market, you should parcel out time to evaluate your portfolio for stocks to sell as we enter 2020.Why? Three reasons: * Too far, too fast. Let's say you own a stock that has soared far above the market. The position that once was 10% of your portfolio is now 35%. That's a lot to have riding on one stock. You don't have to sell your entire holding, but it might be a good idea to trim it back a bit. In fact, you can tie such a move into charitable giving and dodge that pesky capital-gains tax. * Slowdown ahead. Even if your stock has had a whizbang year, you should review it to see if the enthusiasm was a bit overblown. Some stocks that once had stellar records - we're looking at you, Freddie Mac (FMCC) and GameStop (GME) - weren't able to keep the earnings momentum going. If it looks like your stock's growth might be slowing, you should think about where that money could be working a bit harder. Even great buys become stocks to sell at some point. * Right stock, wrong time. Finally, some companies are just in the wrong place at the wrong time, such as energy: the market's worst sector (by a mile) in 2019. Are there good energy stocks? Absolutely. But sometimes, market factors (such as oil prices) punish even the best firms.No one likes selling stocks. You've probably put a lot of work and worry into researching your stocks and holding on to them. But it's an important part of investing, and some of the best investors are not only good buyers of stock, but good sellers. Here then, are five stocks to sell in 2020. SEE ALSO: 43 Companies Amazon Could Destroy (Including One for a Second Time)

  • Reuters

    Bristol-Myers business development head Biondi departs

    Bristol-Myers Squibb Co's head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday. Biondi joined Bristol-Myers in 2002 and had been in charge of business development, helping the company pursue strategic partnerships and deals, since 2015. Bristol-Myers announced the Celgene acquisition last January and the deal closed on Nov. 28.

  • Thomson Reuters StreetEvents

    Edited Transcript of FIVE earnings conference call or presentation 4-Dec-19 9:30pm GMT

    Q3 2019 Five Below Inc Earnings Call

  • If You Had Bought Healthpeak Properties (NYSE:PEAK) Stock Five Years Ago, You'd Be Sitting On A 26% Loss, Today
    Simply Wall St.

    If You Had Bought Healthpeak Properties (NYSE:PEAK) Stock Five Years Ago, You'd Be Sitting On A 26% Loss, Today

    In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

  • Nordson's (NDSN) Q4 Earnings Surpass Estimates, Rise Y/Y
    Zacks

    Nordson's (NDSN) Q4 Earnings Surpass Estimates, Rise Y/Y

    Nordson's (NDSN) fourth-quarter fiscal 2019 earnings increase year over year on account of rise of sales.

  • Investopedia

    8 Stocks That Can Lead as Labor Costs Squeeze S&P Margins

    Goldman Sachs says that stocks with low ratios of labor costs to revenue are poised to be market leaders amid a tight job market.

  • Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
    MarketWatch

    Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting

    A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.

  • Big Oil’s Wishlist: The Hottest Oil Auctions In 2020
    Oilprice.com

    Big Oil’s Wishlist: The Hottest Oil Auctions In 2020

    2020 could see a number of high-profile oil auctions, and where 2019 was a mixed bag in terms of asset assets, this year is shaping up to be more promising

  • Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days
    Investor's Business Daily

    Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days

    Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.

  • Benzinga

    How TD Ameritrade Clients Positioned Themselves In Disney And Tesla After November's Disney+ And Cybertruck Events

    TD Ameritrade Holding Corp. (NASDAQ: AMTD) clients were net buyers of Walt Disney Co (NYSE: DIS) during November following Disney’s release of its highly anticipated streaming service Disney+. This is according to the TD Ameritrade IMX, a monthly measure of buying and selling activity among the firm’s clients. Shares of Disney hit an all-time high on Nov. 26 after it was reported that the streaming platform was averaging 1 million new subscribers per day.

  • Truist exec Johnny Moore sees baby boomer legacies, more M&A activity on the horizon
    American City Business Journals

    Truist exec Johnny Moore sees baby boomer legacies, more M&A activity on the horizon

    The U.S. and China may be trying to negotiate an end to their trade war continues, many local businesses have prepared for difficult times by stocking up on inventory. That, along with merger activity and baby boomer legacies are among the trends observed by Truist exec Johnny B. Moore Jr.

  • Barrons.com

    Saudi Aramco Stock Popped 10% on First Day of Trading. Steer Clear.

    The Saudi royal family celebrated, but it is hard for investors to assess the listing. Political incentives and the stock’s small float make it hard to argue this is a natural price.

  • Reuters

    Brazil's Petrobras likely to hit upper end of target for 2019 production: exec

    Brazilian state-run oil firm Petrobras will produce more than 2.7 million barrels of oil equivalent per day (boepd) in 2019, with total production coming in on the upper end of the target range, an executive said on Wednesday. In its formal guidance, Petroleo Brasileiro SA, as the firm is formally known, predicted it would produce 2.7 million boepd in 2019, though actual production could vary 2.5% above or below the target.

  • Barrons.com

    Chevron Is Taking a $10 Billion Write Down. Here’s Why.

    Chevron announced its capital spending plans for 2020—and also said it was taking a $10 to $11 billion asset write down, mainly related to natural gas related assets. That could move energy sector stocks in Wednesday trading.

  • Benzinga

    The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • Davis Cos. sells Alewife lab for $332.5M
    American City Business Journals

    Davis Cos. sells Alewife lab for $332.5M

    The speculative property was completed last November and has since been fully leased to five biopharmaceutical/biotech companies.

  • These Are The 5 Best Stocks To Buy And Watch Now
    Investor's Business Daily

    These Are The 5 Best Stocks To Buy And Watch Now

    Buying the right stocks at the right time is key to investing. Check out Splunk, Fortinet, AutoZone, Inphi and Pan American Silver.

  • Why Biotech ETFs are Surging to New Highs
    Zacks

    Why Biotech ETFs are Surging to New Highs

    increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

  • Reuters

    Brazil's Petrobras mulls new $400 mln lubricant plant

    Brazil's state-controlled oil company Petrobras SA is mulling construction of a new lubricant plant that could quadruple its production capacity by 2022, the company's refining chief said on Tuesday. Anelise Lara, Petrobras' refining and natural gas chief, told Reuters the company will invest about $400 million to build the new plant in the Comperj refinery, raising its lubricant production capacity to 225,00 cubic meters. When the Comperj plant is concluded, Petrobras plans to shut down its lubricant production unit at Reduc.

  • National discount retailer to build massive distribution center in Conroe
    American City Business Journals

    National discount retailer to build massive distribution center in Conroe

    A publicly traded discount retail store plans to build its third distribution center nationwide north of Houston.

  • Barrons.com

    Baker Hughes Stock Is a Top Idea at Bank of America. That’s Good For GE.

    Analyst Chase Mulvehill put Baker Huges on Bank of America’s “U.S. 1” list—a collection of the bank and brokerage firm’s best ideas. General Electric has more than $8 billion worth of Baker shares.